CORONA Remedies acquires ‘Wokadine’ from Dr. Reddy’s Laboratories

31 Mar 2026 Evaluate

CORONA Remedies has acquired ‘Wokadine’ from Dr. Reddy’s Laboratories. Effective March 30, 2026, the acquisition of Wokadine, ranked second in the Povidone Iodine India market, reinforces CORONA’s commitment to ‘Healing’ as the journey towards holistic recovery and health. This strategic acquisition enables CORONA Remedies to penetrate deeper into targeted specialty and offer wider accessibility. This brand holds strong potential for accelerated growth under CORONA Remedies’ stewardship.

Integrating Wokadine into its portfolio marks CORONA Remedies' entry into the Rs 648 crore Povidone Iodine market. CORONA Remedies' sales & marketing team along with extensive distribution network will work to ensure that this newly acquired portfolio reaches patients across metro, semi-metro, urban, semi-urban and rural areas. Wokadine comprises of 14 SKUs having different applications, helping clinicians treat the ailing community. This acquisition will be fully funded through Company’s internal accruals and cash.

CORONA Remedies is primarily engaged in the business of manufacturing, trading and marketing of pharmaceutical products.

CORONA Remedies Share Price

1556.15 -24.00 (-1.52%)
30-Mar-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1757.35
Dr. Reddys Lab 1254.65
Cipla 1223.05
Zydus Lifesciences 871.20
Lupin 2312.70
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×